Beyond heparin and warfarin: the new generation of anticoagulants (Q33374258)

26 July 2017

1 reference

title

Beyond heparin and warfarin: the new generation of anticoagulants (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

1

Jeffrey I Weitz

1 reference

26 July 2017

Lori-Ann Linkins

2

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Investigational Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

16

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

271-282

1 reference

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Tissue-type plasminogen activator (t-PA) is stored in Weibel-Palade bodies in human endothelial cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Human protein C receptor is present primarily on endothelium of large blood vessels: implications for the control of the protein C pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Anticoagulant repertoire of the hookworm Ancylostoma caninum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Minor transplacental passage of fondaparinux in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Comparison of fondaparinux and enoxaparin in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A Phase II evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

Oral direct thrombin inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/13543784.16.3.271

10.1517/13543784.16.3.271

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference